Amplia Therapeutics Ltd has released a press release.
Amplia Receives $1.1m R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- New Garvan Publication Supports Amplia Phase 2 Design
- Phase 2 Trial in First-Line Pancreatic Cancer Patients
- AGM - Chief Executive Officers Presentatioin
- Quarterly Activities and Cashflow Reports and Presentation
- Results from Successful Phase 1 Clinical Trial of AMP945
Later from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
- Placement and Underwritten Entitlement Offer to Raise $12.4m
- Entitlement Offer Prospectus
- Capital Raising Investor Presentation
- Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics